| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-03-09 | Dynacure (France) | chief executive officer, chief operating officer, chief development officer, members of the board of directors | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2017-03-08 | BergenBio (Norway) Merck&Co (USA - NJ) | BGB324 and pembrolizumab | dvanced non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC). | clinical research | Cancer - Oncology | Clinical research agreement |
| 2017-03-07 | BeiGene (China) Guangzhou GET Technology Development (China) BeiGene Biologics | commercial-scale biologics manufacturing facility in Guangzhou | joint-venture | Joint-venture agreement | ||
| 2017-03-06 | Argen-X (Belgium) Staten Biotech | SIMPLE Antibody™ platform, ARGX-116 | dyslipidemia | licensing - development | Cardiovascular diseases - Metabolic diseases | Exercise of an option agreement |
| 2017-03-06 | Theratechnologies (Canada) TaiMed Biologics (Taiwan) | ibalizumab | HIV infection | marketing - distribution | Infectious diseases | Commercialisation agreement |
| 2017-03-06 | Servier (France) Vernalis (UK) | R&D - research | Cancer - Oncology | Research agreement | ||
| 2017-03-06 | Polyphor (Switzerland) | nomination | Infectious diseases | Nomination | ||
| 2017-03-06 | Amag Pharmaceuticals (USA - MA) | nomination | Nomination | |||
| 2017-03-06 | Vertex Pharmaceuticals (USA - MA) Concert Pharmaceuticals (USA - MA) | CTP-656 (D9-ivacaftor ) deuterated ivacaftor | cystic fibrosis (CF) | product acquisition | Rare diseases - Genetic diseases - Lung diseases | Product acquisition |
| 2017-03-02 | Boehringer Ingelheim (Germany) Vanderbilt University (USA -TN) | small molecule inhibitors of oncogenic Ras | research - R&D | Cancer - Oncology | Research agreement | |
| 2017-03-02 | Melinta Therapeutics (USA - CT) Menarini (Italy) | Baxdela® (delafloxacin) | acute bacterial skin and skin structure infections (ABSSSI), hospital-treated community-acquired bacterial pneumonia (hCABP) | development - commercialisation | Infectious diseases | Development agreement |
| 2017-03-02 | Allergopharma (Germany) Merck KGaA (Germany) | biopharmaceutical production plant | opening of new premises | Opening of new premises | ||
| 2017-03-02 | Bioverativ (USA - MA) | member of the board of directors | nomination | Rare diseases - Genetic diseases - Hematological diseases | Nomination | |
| 2017-03-02 | Arix Bioscience (UK) Takeda Ventures (USA - CA)) | collaboration | Cancer - Oncology - Gastrointestinal diseases | Collaboration agreement | ||
| 2017-03-01 | Theradiag (France) | nomination | Technology - Services | Nomination | ||
| 2017-03-01 | Adaptimmune (UK) | U.S. headquarters | opening of new premises | Cancer - Oncology | Opening of new premises | |
| 2017-02-28 | Veloxis Pharmaceuticals (Denmark) | restructuring | Restructuring | |||
| 2017-02-28 | Crispr Therapeutics (Switzerland - USA - MA) | nomination | Nomination | |||
| 2017-02-27 | Argen-X (The Netherlands-Belgium) Shire (UK-USA) | therapeutic antibodies based on arGEN-X\'s SIMPLE Antibody™ technology | development | Rare diseases - Genetic diseases | Development agreement | |
| 2017-02-27 | CTI BioPharma - previously known as Cell Therapeutics (USA - WA) | nomination | Cancer - Oncology | Nomination |
